Cargando…

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yifan, Song, Jialong, Li, Xinyi, Luo, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408844/
https://www.ncbi.nlm.nih.gov/pubmed/36012144
http://dx.doi.org/10.3390/ijms23168878
_version_ 1784774701766148096
author Ren, Yifan
Song, Jialong
Li, Xinyi
Luo, Na
author_facet Ren, Yifan
Song, Jialong
Li, Xinyi
Luo, Na
author_sort Ren, Yifan
collection PubMed
description Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
format Online
Article
Text
id pubmed-9408844
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94088442022-08-26 Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer Ren, Yifan Song, Jialong Li, Xinyi Luo, Na Int J Mol Sci Review Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC. MDPI 2022-08-10 /pmc/articles/PMC9408844/ /pubmed/36012144 http://dx.doi.org/10.3390/ijms23168878 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ren, Yifan
Song, Jialong
Li, Xinyi
Luo, Na
Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title_full Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title_fullStr Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title_full_unstemmed Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title_short Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
title_sort rationale and clinical research progress on pd-1/pd-l1-based immunotherapy for metastatic triple-negative breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408844/
https://www.ncbi.nlm.nih.gov/pubmed/36012144
http://dx.doi.org/10.3390/ijms23168878
work_keys_str_mv AT renyifan rationaleandclinicalresearchprogressonpd1pdl1basedimmunotherapyformetastatictriplenegativebreastcancer
AT songjialong rationaleandclinicalresearchprogressonpd1pdl1basedimmunotherapyformetastatictriplenegativebreastcancer
AT lixinyi rationaleandclinicalresearchprogressonpd1pdl1basedimmunotherapyformetastatictriplenegativebreastcancer
AT luona rationaleandclinicalresearchprogressonpd1pdl1basedimmunotherapyformetastatictriplenegativebreastcancer